Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Ambry Genetics | RCV002410467 | SCV002716264 | uncertain significance | Hereditary cancer-predisposing syndrome | 2020-08-12 | criteria provided, single submitter | clinical testing | The p.I610V variant (also known as c.1828A>G), located in coding exon 12 of the BRIP1 gene, results from an A to G substitution at nucleotide position 1828. The isoleucine at codon 610 is replaced by valine, an amino acid with highly similar properties. This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
| Labcorp Genetics |
RCV003774519 | SCV004593084 | uncertain significance | Familial cancer of breast; Fanconi anemia complementation group J | 2022-12-09 | criteria provided, single submitter | clinical testing | This sequence change replaces isoleucine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 610 of the BRIP1 protein (p.Ile610Val). This variant is present in population databases (rs749200646, gnomAD 0.0009%). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt BRIP1 protein function. ClinVar contains an entry for this variant (Variation ID: 1780874). This variant has not been reported in the literature in individuals affected with BRIP1-related conditions. |